KhanhC.Hoang

A positive change in its fundamental story.

Long
NASDAQ:HZNP   HORIZON THERAPEUTICS PLC
HZNP announced its intent to acquire Viela Bio which is a biotech company with a mid-stage biologics pipeline in auto-immune and inflammatory conditions. Viela Bio recently (June 2020) launched Uplinza (anti-CD19 antibody) in the US for NMOSD (rare ocular disorder). Viela Bio's platform of three unique biologic molecules with 9 potential indications as drivers for the “long-term” value of the deal while Uplinza’s NMO marketed indication is a short-term value driver.

Comments

Home Stock Screener Forex Screener Crypto Screener Economic Calendar About Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Private Messages Chat Sign Out